RT Conference Proceedings
T1 Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
A1 Neukam, Karin
A1 Espinosa, Nuria
A1 Merino, Dolores
A1 Rivero-Juárez, Antonio
A1 Carrero, Ana
A1 Ríos, María José
A1 Ruiz-Morales, Josefa
A1 Gómez-Berrocal, Ana
A1 Téllez, Francisco
A1 Díaz-Menéndez, Marta
A1 Collado, Antonio
A1 Pérez-Camacho, Inés
A1 Delgado-Fernández, Marcial
A1 Vera-Méndez, Francisco
A1 Pineda, Juan A.
K1 Liver
K1 Emtricitabine, Rilpivirine, Tenofovir Drug Combination
K1 Spain
K1 Tablets
K1 Transaminases
AB Although hepatotoxicity related to antiretroviral treatment (ART) has become less frequent, hepatotoxic events,such as transaminase elevations (TE), are still a matter of concern. RPV/FTC/TDF (EPA) is a new single tablet regimen which iswidely used in real life practice. Clinical trials showed an adequate profile of liver safety in the sub-population of HIV/HCV-coinfected patients receiving rilpivirine. However, the number of individuals included in these analyses is low [1]. The aim of thisongoing study is to evaluate the incidence of TE and total bilirubin elevations (TBE) during the first 48 weeks of EPA-basedtherapy in a large population of HIV/HCV-coinfected subjects outside of clinical trials.
PB BioMed Central
YR 2014
FD 2014-11-02
LK http://hdl.handle.net/10668/2533
UL http://hdl.handle.net/10668/2533
LA en
NO Neukam K, Espinosa N, Merino D, Rivero-Juárez A, Carrero A, Ríos Mj,  et al. Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study. J Int AIDS Soc.. 2014, 17(Suppl 3):19631
DS RISalud
RD Aug 17, 2025